RxDoctor Payments Data

Karima Khimani, MD

Cornea and External Diseases Specialist · San Antonio, TXNPI 1609371715

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,074 of the $1,255 with a category attached, or 85.6%. 8 manufacturers reported payments, led by Alcon at 52.8% of the total. 2025 is the largest year on record at $581, 6.5 times the $89 reported in 2022.

$1,255in general payments, 2019–2025

Across 22 payments — averaging $57.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$663
  • AbbVie$240
  • Rxsight Inc$131
  • Bausch & Lomb Americas Inc.$112
  • Astellas Pharma US Inc$54
  • Tarsus Pharmaceuticals, Inc.$23
  • plus $31 from 2 others

What the payments were for

  • Travel & lodging$18014%
  • Food & beverage$1,07486%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,255 in reported general payments places this provider in the 55th percentile of 35 cornea and external diseases specialist providers in Texas.

See all cornea and external diseases specialist providers in Texas

Medicare billing

Part B allowed, 2024
$142,665
Medicare patients
467
Services billed
1,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate99$5,235
LumiganBimatoprost12$4,354
Loteprednol Etabonate12$2,014
ValacyclovirValacyclovir Hcl23$1,650
MoxifloxacinMoxifloxacin Hcl54$1,402
Latanoprost118$943
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$389
Ofloxacin20$353
Cromolyn Sodium16$330
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha29$284
ErythromycinErythromycin Base25$274
Doxycycline Hyclate15$151
Brimonidine Tartrate14$73
Timolol Maleate20$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$240$4,35412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 35 cornea and external diseases specialist providers in Texas.

Other cornea and external diseases specialist in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →